Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Yair Levy, Nina Kim, Siraje Mahmud, Bingcao Wu, Laura Ensley, Dee Lin, Monica Lisi, Felice Yang, Lorraine Brisbin, Jessica Fowler, Laura Hester, Agne Paner-Straseviciute, Sian Walker, Christina Hearty, R. Steven Paulson

Blood (2024) 144 (Supplement 1): 7851.

https://doi.org/10.1182/blood-2024-210497

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7843.

https://doi.org/10.1182/blood-2024-208708

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7854.

https://doi.org/10.1182/blood-2024-210841

Published: 2024

Journal Articles

Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Robert Rifkin, Henning Schade, Gary Simmons, Christopher Yasenchak, Jessica Fowler, Thomas S. Lin, Lijuan Kang, Weiming Xu

Blood (2024) 144 (Supplement 1): 4753.

https://doi.org/10.1182/blood-2024-207295

Published: 2024

Journal Articles

Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Aimaz Afrough, Adeel M Khan, Eric Chinaeke, Nina Kim, Jinghua He, Elissa E. Min, Bingcao Wu, Dee Lin, Agne Paner-Straseviciute, Laura Hester, Jessica Fowler, Sian Walker, Christina Hearty, Larry D Anderson, Jr.

Blood (2024) 144 (Supplement 1): 933.

https://doi.org/10.1182/blood-2024-209008

Published: 2024

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Rahul Banerjee, Nina Kim, Monal Kohli, Emeka Umeh, Dee Lin, Gideon Aweh, Jessica Fowler, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Bingcao Wu

Blood (2024) 144 (Supplement 1): 3792.7.

https://doi.org/10.1182/blood-2024-210750

Published: 2024

Journal Articles

Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

Robert M. Rifkin, Jeff P. Sharman, Jessica Fowler, Thomas S. Lin, Brian Thomson, Jesus G. Berdeja

Blood (2023) 142 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2023-185257

Published: 2023

Journal Articles

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Carlyn Rose Tan, Nina Kim, Eric Chinaeke, Laura Hester, Jessica Fowler, Dina Gifkins, Dee Lin, Sian Walker, Alex Z. Fu, Bingcao Wu

Blood (2023) 142 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2023-178896

Published: 2023

Journal Articles

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Rahul Banerjee, Nina Kim, Monal Kohli, Laura Hester, Emily Achter, Jessica Fowler, Emeka Umeh, Dee Lin, Gideon Aweh, Dina Gifkins, Sian Walker, Bingcao Wu

Blood (2023) 142 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2023-178908

Published: 2023

Journal Articles

Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study

Ben A Derman, Meaghan Roach, Dee Lin, Bingcao Wu, Richard Murphy, Nina Kim, Margaret Doyle, Nadya Prood, Jessica Fowler, Alexander Marshall, Amal Jamaleddine, Agne Paner-Straseviciute

Blood (2023) 142 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2023-187479

Published: 2023

Journal Articles

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Tyler B. Sandahl, Scott A. Soefje, Ediz S. Calay, Yi Lin, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Eli Silvert, Nina Kim, Corinne Carpenter, Tyler E. Wagner, Jessica Fowler, Laura Hester, Alexander Marshall, Patrick Stoy, Dina Gifkins, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2023-174270

Published: 2023

Journal Articles

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Daanish Hoda, Edward Faber, Jr., Bradley Hunter, Abhinav Deol, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C. Jackson, Jessica Fowler, Ariel Berger, Andrea L Lorden, Raj Stewart

Blood (2021) 138 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2021-145943

Published: 2021

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Katja Weisel, MD, George F. Geils, MD, Lionel Karlin, MD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Tae-Hoon Chung, Chang-Ki Min, MD PhD, Kazutaka Sunami, MD PhD, Amanda Goldrick, MD, Belle Fang, Jessica Fowler, PhD, Maria-Victoria Mateos, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133908

Published: 2020

NARROW

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only